✦ LIBER ✦

Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors

✍ Scribed by Isis Torréns; Osmany Mendoza; Aileen Batte; Osvaldo Reyes; Luis E. Fernández; Circe Mesa; Gerardo Guillén

Book ID: 116958260
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 219 KB
Volume: 23
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2005.07.049

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antigen-specific immunotherapy for murin

Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein

✍ Hongxiu Ji; Edwin Y. Chang; Ken-Yu Lin; Robert J. Kurman; Drew M. Pardoll; T.-C. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 465 KB

An important goal of cancer immunotherapy is to prevent and treat tumor metastasis. We have previously reported a recombinant vaccinia-based vaccine (Sig/E7/LAMP-1) that demonstrated significant anti-tumor effect in a subcutaneous tumor challenge model. In this study, we investigated the potency of

Vaccination with an adenoviral vector ex

Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice

✍ Jorge G. Gomez-Gutierrez; Kutlu G. Elpek; Roberto Montes de Oca-Luna; Haval Shir 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 549 KB

A novel fusion protein-based vaccine com

A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice

✍ Milaid Granadillo; Maribel G. Vallespi; Aileen Batte; Osmany Mendoza; Yordanka S 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 673 KB